At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 450 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
DHEA 3.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
In Brief
A Phase 3 clinical trial evaluating Placebo and DHEA for Vaginal Atrophy. Completed, enrolled 450 participants across 42 sites in 2 countries.
Detailed Summary
The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaginal Atrophy
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionApr 2012
Study CompletionMay 2012
TodayJul 2026
First PostedMay 24, 2011
Enrollment StartJun 1, 2011
Primary CompletionApr 1, 2012
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.1 years ago
Interventions
Placebodrug
Placebo vaginal suppository
DHEAdrug
Vaginal suppository containing 0.25% (3.25 mg) DHEA
DHEAdrug
Vaginal suppository containing 0.5% (6.5 mg) DHEA